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The objective of this study was to prepare and evaluate chronotherapeutic drug delivery systems (ChrDDs) 
of torsemide. Compression coated tablets (CCT) containing torsemide in the core tablet were prepared by 
the compression coating technique with different grades of polyethylene oxide (PEO WSR 301 & 1105). 
The optimized formulations were characterised for tabletting parameters and drug polymer interaction 
by Fourier-Transform Infrared Spectroscopy (FTIR).The hardness of all the CCT using PEO WSR 301 
& PEO WSR 1105 were in the range 6-8 kg/cm2 & 5.5 to 7 kg/cm2 respectively. Their friability values 
were <0.3%. All the CCT showed a clear lag time but finalized as per the predetermined lag time. As the 
amount of PEO was increased in the outer layer the drug released was delayed. The drug content of all the 
CCT was ≥99%. The FTIR studies showed no interaction throughout the process of development. Formu-
lations of F7 and of P7 were considered optimized formulations since they yielded a predetermined lag 
time of 6h before burst release. Hence, these formulations can be exploited to achieve chronotherapeutic 
drug delivery systems of Torsemide for the treatment of hypertension at the  time the patient needs it. 
Uniterms: Torsemide. Chronotherapeutic drug/delivery systems. Polyethylene Oxides. Compression 
coated tablets. Predetermined lag time.
O objetivo deste estudo foi preparar e avaliar sistemas cronoterapêuticos de liberação de fármacos  
(ChrDDs) de torsemida. Comprimidos revestidos por compressão (CCT) contendo torsemida no  (núcleo) 
foram preparados pela técnica de revestimento por compressão, com diferentes categorias de óxido de 
polietileno (PEO WSR 301 & 1105). As formulações otimizadas foram caracterizadas por parâmetros 
de compressão e interação fármaco polímero por Infravermelho com Transformada de Fourier (FTIR). 
A dureza dos CCT utilizando PEO WSR 301 e PEO WSR 1105 foi entre 6-8 kg/cm2 e 5,5 a 7 kg/cm2, 
respectivamente. Os valores de friabilidade foram <0,3%. Todos os CCT mostraram claro tempo de 
retardo, mas finalizaram de acordo com o tempo de retardo pré-determinado. À medida que a quantidade 
de PEO aumentava na camada mais externa, a liberação do fármaco era retardada. O teor de fármaco 
em todos os CCT foi ≥99%. Os estudos de FTIR mostraram que não h[a interação durante o processo de 
desenvolvimento. As formulações F7 e P7 foram consideradas otimizadas, uma vez que resultaram em 
tempo de retardo pré-determinado de 6 h antes da liberação por meio de explosão. Dessa forma, estas 
formulações podem ser exploradas para se obter sistemas de liberação.
Unitermos: Torsemida. Sistemas de liberação cronoterapêutica/liberação de fármacos. Óxidos de 
polietileno. Comprimidos cobertos por compressão. Tempo de retardo pré-determinado.
INTRODUCTION
Hypertension is a chronic disorder and the symp-
toms of the disease are pronounced predominantly during 
the early hours of the morning (Ura  et al., 1992). The 
treatment of this disease condition occurring in the early 
hours is not convenient by using the existing marketed 
conventional immediate release dosage form. Hence, a 
Chronotherapeutic drug delivery system (ChrDDs) with a 
predetermined lag time may be useful for such patients as 
the drug is released at a predetermined time and hence the 
S.A. Sunil, N.S. Rao, M.V. Srikanth, M.U. Uhumwangho, K.S.P. Kumar, K.V.R. Murthy594
maximum concentration (Cmax) of the drug can be reached 
when the symptoms of the disease are worse to fatal. It 
will be more helpful if antihypertensive patients take the 
medication before bed time to overcome a high level of 
discomfort in the morning (Smolensky et al.,1997; Efen-
takis et al.,2006). It is also thought that ChrDDs may be a 
successful tool for effective chronopharmacotherapy be-
cause of their unique drug release properties, which could 
take advantage of circadian rhythms in physiologic and 
pathologic conditions (White et al., 1992). An ideal oral 
ChrDDs would overcome the problem of administering 
the drugs frequently. The advantages of ChrDDs include 
convenience, reduced dosing frequency, reduced toxicity 
and decreased total required therapeutic or instantaneous 
preventive drug dose level matching exactly the biological 
and physiological needs to treat the disease at each point 
in time. Ultimately, this should lead to improved patient 
compliance.   
Compression-coated tablets (CCT) are dosage forms 
that consist of an inner core immediate release tablet embe-
dded in an outer layer compartment, which contains either 
a hydrophilic, hydrophobic or a mixture of both polymers. 
The outer layer dissolves or disintegrates slowly to release 
the drug after a predetermined lag time. The advantage of 
this technique is that it is simply achieved by minor modi-
fication of existing equipment, inexpensive, is capable of 
physically separating two incompatible drugs within the 
same dosage form, allows taste masking of bitter drugs 
and is not hazardous to the environment, since it does not 
require the use of organic solvent (Hadfield et al., 1987; 
Oth et al., 1993).
Previously, Conte et al., 1993 formulated a novel 
dry-coated device for the release of drug after a program-
mable period of time. It was intended to be used mainly in 
the therapy of those diseases which depend on circadian 
rhythms. CCT of aminophylline using crystalline cellulose 
and polyethylene glycol as coating polymers in the outer 
shell for timed-release dosage forms to achieve chrono-
pharmacotherapy for asthma has also been developed 
(Watanabe et al., 2002). Recently, Sawada et al. (2004) 
also designed a CCT of nifedipine by using the dry coating 
technique with different polyethylene oxide-polyethylene 
glycol mixtures. Each formulation showed a clear lag 
period before the drug release. This was also followed by 
sustained drug release lasting up to 24 h.
Torsemide is a pyridine-sulfonylurea type loop 
diuretic indicated for the treatment of hypertension and 
edema in congestive heart failure. It may be used alone or 
in combination with thiazide diuretics. Its chemical name 
is N-[(isopropylamino)carbonyl]-4-[(3-methylphenyl)
amino]pyridine-3-sulfonamide with a molecular formula 
of C16H20N4O3S
 (Groop et al.,1989.). Its oral bioavailabili-
ty is around 75-89% with a biologic half-life of about 3.5 h 
(Martindale, 2005).The usual initial dose is 5 mg once 
daily which may be increased to 10, 20 and 100 mg once 
daily. ChrDDs are designed such that the Cmax of the drug 
is reached at the maximum intensity of disease condition. 
Hence, the purpose of this study was to design an optimi-
sed ChrDDs of Torsemide with different grades and ratios 
of Polyethylene Oxide water soluble resins (PEO WSR) 
including PEO WSR 301 and PEO WSR 1105 to obtain 
the predetermined lag time of 6 hrs, after which the drug 
is released. PEO WSR is as a nonionic homopolymer of 
ethylene oxide, represented by the formula (CH2CH2O)
n, where n represents the average number of oxyethylene 
groups. It may contain up to 3% silicon dioxide or suitable 
antioxidant. It is soluble in water as well as in a number of 
common organic solvents such as acetonitrile, chloroform, 
and methylene chloride. Moreover, it is insoluble in ali-
phatic hydrocarbons, ethylene glycol, and most alcohols.
MATERIAL AND METHODS
Materials
Torsemide, different grades of polyethylene oxi-
des, directly compressible lactose (DCL 21), sodium 
starch glycolate, crospovidone, sodium croscarmellose, 
povidone K 30 and poloxamer 188 were Gift samples 
from Macleods Pvt.Ltd., Mumbai, India. Avicel pH 101 
was obtained as a gift sample from FMC biopolymer 
and magnesium stearate was purchased from S.D. Fine 
Chemicals Ltd., Mumbai. All other reagents used were of 
analytical grade. 
Methods
Preparation of an optimised core tablet
Based on preliminary studies in our laboratory, an 
optimized immediate release core tablet was developed 
by using varying concentrations and different diluents, 
disintegrant and binder. The drug, diluents, disintegrant 
and binder were weighed for a batch of 100 tablets as 
per formulae given in Table I. These were then passed 
through a # 40 (420 µm) sieve, transferred to a poly bag 
and blended for 5 minutes. Magnesium stearate passed 
through a # 60 (250 µm) sieve was added to the homoge-
neous mixture and blended for 2 minutes. The resulting 
blend was compressed with a rotary compression machine 
(Model Riddhi, Ahmedabad) to form a bi convex tablet 
with a diameter of 6mm to a hardness of 2.5±0.2 kg/cm2. 
The weights of the tablets were 100±0.8 mg. The batch 
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that gave a comparable release profile with the marketed 
tablet (TIDE 20) was considered an optimised core tablet.
Preparation of Timed-release compression-coated 
tablets (CCT)
The required polymer (PEO WSR 301 or PEO WSR 
1105) was weighed for a batch of 100 tablets as per for-
mulae given in Table II and III and passed through a # 40 
sieve and transferred to a poly bag. Magnesium stearate 
passed through # 60 sieve was added to the above mixture 
and blended for 2 minutes for lubrication of the blend. 
Half the amount of the thoroughly mixed homogeneous 
polymer blend was placed in the die to make a powder 
bed.  The core tablet previously developed and optimised 
was carefully placed at the centre on the polymer bed and 
the remaining half of the homogeneous polymer blend 
was filled into the die. The contents were then compres-
sed using a rotary compression machine (Model Riddhi, 
Ahmedabad) to form a bi convex tablet with a diameter of 
9 mm & 12 mm depending on the weight.
Physicochemical evaluation of tablets
·	 Determination of tablet hardness and friability 
(Banker et al., 1991; Marshall et al., 1991)
The fracture loads (kg) of ten tablets were deter-
mined individually with a Monsanto hardness tester. The 
mean values of the fracture loads were recorded. The fria-
bility test is to evaluate the ability of the tablet to withstand 
abrasion in packaging, handling and shipping. Tablets 
were taken, equivalent to 6.5 gm which was denoted as 
initial weight (w1), placed in friabilitator (Roche) and allo-
wed to rotate at 25 rpm for 4 min. After four minutes of this 
treatment or 100 revolutions, the tablets were weighed and 
the result (w2) compared with the initial weight. The loss 
TABLE I - Formulae of core tablets
Ingredients (mg) TC 1 TC 2 TC 3 TC 4 TC 5 TC 6 TC 7 TC 8
Torsemide 20 20 20 20 20 20 20 20
DCL 21 20 40 60 72 73 73 72 71
Avicel PH 102 53 33 13 0 --- --- --- ---
Crospovidone 3 3 3 4 -- -- 4 4
Sodium starch glycolate --- --- --- --- 4 --- --- --
Sodium croscarmellose --- --- --- --- --- 4 -- ---
Povidone K 30 3 3 3 3 2 2 2 2
Poloxamer 188 --- --- --- -- -- -- 1 2
Magnesium stearate 1 1 1 1 1 1 1 1
Total Weight (mg) 100 100 100 100 100 100 100 100
TABLE II - Coated tablet composition of PEO WSR 301 tablets
Ingredients (mg) F 1 F 2 F 3 F 4 F 5 F 6 F 7
Core 100 100 100 100 100 100 100
PEO WSR 301 160 180 200 220 240 260 210
Magnesium stearate 2.4 2.7 3.0 3.3 3.6 3.9 3.15
Total weight (mg) 262 282.7 303 323.3 343.6 363.9 313.15
TABLE III - Coated tablet composition of PEO WSR 1105 tablets
Ingredients (mg) P 1 P 2 P 3 P 4 P 5 P 6 P 7
Core 100 100 100 100 100 100 100
PEO WSR 1105 400 500 600 430 450 470 440
Magnesium stearate 6 7.5 9 6.45 6.75 7.05 6.6
Total weight (mg) 506 607.5 709 536.45 556.75 577.05 546.6
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due to abrasion is a measure of tablet friability. The % fria-
bility was calculated by using the equation given below.
% Friability = (w1 - w2) x 100/ w1     
·	Drug Content
In order to determine the content of Torsemide pre-
sent in the tablets, five tablets were weighed and crushed 
to fine powder. Powder equivalent to 20 mg of drug was 
weighed and transferred into a 100 mL volumetric flask 
and diluted to 100 mL with 6.8 phosphate buffer. The 
resulting solution was filtered with Whatman No. 3 filter 
paper. The sample was suitably diluted and analyzed for 
drug content by using UV-spectrophotometer (Elico SL 
210) at 285.5 nm. 
·	In vitro drug release studies
The prepared core and compression coated tablets 
were subjected to in-vitro drug release studies in suitable 
dissolution media for 60 min and 8-12 h respectively to 
assess their ability to provide the desired release. The 
in-vitro drug release studies were performed using a USP 
Type I dissolution apparatus. The dissolution medium for 
the core tablets was 900 mL of 6.8 pH phosphate buffer for 
60 min and for compression coated tablets was 0.1 N HCl 
for the first 2 h  followed by 6.8 pH phosphate buffer for 
the remaining period. As the maximum drug release was 
targeted for a predetermined lag time of 6 h, after about 
6 h the tablet would be in the region of the small intestine. 
Since the majority of drugs are well absorbed from this 
region, whose pH is 6.8, the 6.8 pH phosphate buffer was 
selected as the dissolution media. The temperature of 
dissolution medium was maintained at 37 ± 0.5 °C. The 
tablet was introduced into the basket, and then lowered 
such that the lower end of the basket was 25 mm above the 
base of the beaker which was set to rotate at 100 rpm. In 
all experiments, an aliquot of 5 mL sample of the leaching 
fluid was withdrawn at predetermined time intervals with 
a syringe fitted with a filter and replaced with an equal 
volume of drug-free dissolution fluid in order to maintain 
the sink condition. The samples were filtered and analyzed 
spectrophotometrically at 285.5 nm by using an Elico SL 
210 UV-Visible double beam spectrophotometer (Elico, 
India). The amounts released were expressed as a percen-
tage of the drug content in each dissolution medium. The 
dissolution test was carried out in triplicate and the mean 
results were reported.
·	Fourier Transform Infrared Spectroscopy (FTIR)
The FTIR spectrum of the different samples were 
recorded on an Infra Red spectrometer (Nicolet Magna 4R 
560, MN, USA) using potassium bromide discs prepared 
from powdered samples. The spectrum was recorded in 
the region of 4000 to 400 cm-1. 
RESULTS AND DISCUSSION
Physicochemical parameters of the core tablets
Core tablets were evaluated for physicochemical 
parameters including hardness, friability, disintegration 
and drug content. Hardness was in the range 2-4 kg/cm2, 
friability was <0.45%, disintegration (<30 sec) and drug 
content was >99.0%. Results are given in Table IV.
Physicochemical parameters of CCT
CCT formulations (PEO WSR 301 and 1105) were 
evaluated for their physicochemical parameters including 
hardness, friability and drug content. The tablet hardness 
values for formulations with PEO WSR 301 as the polymer 
was between 6 and 8 kg/cm2 while those prepared with 
PEO WSR 1105 ranged from 5.5 to 7.0 kg/cm2. The slight 
difference in the hardness might be attributable to the va-
riation in tablet weight. However, these values did not vary 
significantly (p > 0.05). The percentage friability of all the 
formulations was <0.30% while the content uniformity of 
the tablets was >99% which indicates uniform distribution 
of drug in the tablets of each formulation. However, all of 
these values were within acceptable compendial limits. 
Results are given in Tables V and VI.
In vitro drug release study of Core tablet
The prepared core tablets were subjected to in vitro 
drug release studies in suitable dissolution media for 60 
TABLE IV - Evaluation of physico-chemical parameters of core 
tablet
Formulation
Hardness 
(kg/cm2)
Friability 
(%)
Drug content* 
(%)
Disintegration 
(sec)
TC 1 4 0.415 99.33±0.81 30
TC 2 4 0.354 100.37±0.76 30
TC 3 3 0.423 100.13±1.19 25
TC 4 2 0.356 99.73±1.66 25
TC 5 4 0.201 100.83±1.57 25
TC 6 4 0.215 100.05±1.00 25
TC 7 3.5 0.420 100.19±1.29 24
TC 8 4 0.349 100.29±1.09 26
* mean±s.d., n=3
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min to assess their drug release. The drug release studies 
were performed on an USP Type I dissolution apparatus 
using 900 ml of 6.8 pH phosphate buffer. The dissolution 
medium was kept in a thermostatically controlled water 
bath, maintained at 37 ± 0.5 o C. The Basket was lowered 
so that the lower end of the stirrer was 25 mm above the 
base of the beaker. The tablet was then introduced into 
the dissolution jar and the basket was rotated at 100 rpm. 
All the dissolution experiments on tablets were done in 
triplicate. Aliquots of 5 mL of sample were withdrawn at 
predetermined time intervals and replaced with an equal 
volume of the fresh dissolution medium to maintain the 
total volume constant. The samples were filtered and 
analyzed spectrophotometrically at 285.5 nm for the drug 
release. The correction factor was included in the calcu-
lation for estimation of the concentration of dissolved 
drug in the dissolution media. Tablets were developed in 
such a way that the tablets had a release that matched the 
marketed tablet. TC 1-7 batches were developed using 
different diluents and disintegrants either alone or in 
combination. TC 8 showed a release profile similar to that 
of the marketed tablet (Tide 20). 2% poloxamer 188 was 
used in the final formulation to achieve a release within 
15 min as shown in Figure 1.
ChrDDs formulations were designed to ensure the 
drug is released at a predetermined lag time so that the 
burst release of the drug could take advantage of circa-
dian rhythms in physiologic and pathologic conditions 
(White et al., 1992). This ultimately reduces toxicity and 
improves patient compliance. Hence, it is important that 
ChrDDs formulations release their drug at the time needed. 
Previously, (Sawada et al., 2003) reported that CCT with 
a greater core erosion ratio, release their drug gradually 
after the predetermined lag time until they have completely 
dissolved. In order to evaluate the performance of these 
formulations so as to release its medication at a predeter-
mined lag time of 6 h, different grades and concentration 
of polyethylene oxide (i:e PEO WSR 301 and 1105) were 
used as an outer coating agent. PEO is a gel-forming 
polymer used to enhance water penetration into the CCT. 
All the dissolution experiments were done in triplicate. F 
1 - 3 batches were taken by using PEO WSR 301 with core: 
polymer at the following ratios1:1.6, 1:1.8 and 1:2 while 
magnesium stearate (1.5%) was added as a lubricant in 
all the formulations. The dissolution profiles of torsemide 
CCT for batch F 1-3 is shown in Figure 2. It was observed 
that the lag time increased as the concentration of the PEO 
in the outer coat increased. For instance, formulation F 1 
had a lag time of 1.5 hrs before burst release. On the other 
hand, F 2 and 3 had lag times of 4 and 5 hrs, respectively. 
It is well known that tablet hardness can affect the release 
rate of a drug (Capan, 1965).  Katikaneni et al. (1995) 
reported that increase in tablet hardness is accompanied 
by a decrease in release rate, due to a decrease in tablet 
porosity.  However, since there was no significant change 
in the tablet hardness of the all the CCT formulations 
with increased concentrations of the PEO, the lag time 
TABLE V - Evaluation of physico-chemical parameters of 
Compression coated tablets of PEO WSR 301
Formulations
Hardness 
(kg/cm2)
Friability 
(%)
Drug content* 
(%)
F 1 7 0.18 100.07±1.65
F 2 6 0.14 99.87±1.19
F 3 6.5 0.17 100.53±1.35
F 4 8 0.12 99.63±0.81
F 5 7 0.14 101.33±1.21
F 6 7 0.15 99.87±0.60
F 7 7 0.12 100.00±1.00
* mean±s.d., n=3
TABLE VI - Evaluation of physico-chemical parameters of 
Compression coated tablets of PEO WSR 1105
Formulations
Hardness 
(kg/cm2)
Friability 
(%)
Drug content 
(%)
P 1 5.5 0.28 99.85±0.65
P 2 6 0.24 100.00±1.00
P 3 7.0 0.27 100.13±0.85
P 4 5.5 0.29 99.86±0.96
P 5 6 0.26 99.49±1.32
P 6 6 0.21 100.07±0.89
P7 6.5 0.22 99.91±0.81
* mean±s.d., n=3
FIGURE 1 - Dissolution profiles of core tablets compared to 
marketed tablet (mean±s.d., n=3).
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of torsemide before burst release might be attributable to 
the high gel-forming ability of the PEO with increase in 
concentration. Given the targeted predetermined lag time 
was 6 hrs, further batches were produced by increasing the 
concentrations of the PEO WSR 301. F 4 - 6 batches were 
produced by using PEO WSR 301 with core: polymer at 
the ratios 1:2.2, 1:2.4 and 1:2.6. The dissolution profile 
of this batch is depicted in Figure 2. The result showed 
that batch 4, 5 and 6 had burst releases of 7, 8 and 9 hrs 
respectively. Hence, the next batch F 7 was produced with 
a concentration of PEO WSR 301 between F 3 & 4. F 7 
and was formulated with a 1:2.1 core: polymer ratio. This 
resulted in drug release with a predetermined lag time 
of 6 hrs and maximum release in 7 hrs. Hence, F 7 was 
considered to be the optimized formulation as the desired 
pre determined lag time was obtained.
In batches P 1-3, PEO WSR 1105 polymer had 
core: polymer ratios of 1:4, 1:5 and 1:6. The dissolution 
profiles of torsemide CCT for batches P 1-3 is shown in 
Figure 3. Magnesium stearate (1.5%) was also incorpo-
rated as the lubricant. The results indicated that that the 
burst release of the drug occurred at 5, 10 and 12 hrs, 
respectively. As the predetermined lag time targeted was 
6 hrs, further batches were also produced by changing 
the concentrations of the polymer to suit the drug release 
for the predetermined lag time of 6 hrs. Hence, P 4 - 6 
batches were produced by using PEO WSR 1105 with 
core: polymer ratios of 1:4.3, 1:4.5 and 1:4.7.  The re-
sults indicated a predetermined lag time of drug release 
of 6, 8 and 9 hrs for formulation 4, 5 and 6, respectively. 
Hence, to achieve the targeted lag time the amount of 
polymer was reduced in P 7 and was formulated with a 
core: polymer ratio of 1:4.4.  The results indicated that all 
the physical parameters were within limits and the drug 
was released within 7 hrs with a predetermined lag time 
of 6 hrs as shown in Figure 3. 
FTIR analysis
FTIR analysis of torsemide individually and in 
combination with other ingredients of core tablets and 
CCT was investigated to identify any chemical inte-
raction between the added excipients and torsemide. 
The major peaks for the pure drug were observed at 
1697.42.31cm-1 (C= N stretch), 1282.15 cm-1 (C-N 
stretch) and 3279.94 cm-1 (presence of hetero atoms). 
The presence of PEO WSR 301 and PEO WSR 1105 
did not produce any major shift in peak characteristics 
of Torsemide as shown in Figure 4 and 5. This indicates 
that there was no chemical interaction between drug and 
the excipients used in the study. 
CONCLUSION
In the present investigation, torsemide was selec-
ted as the drug since the symptoms of hypertension are 
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FIGURE 4 - FTIR spectra of (A) Pure drug (B) PEO 301 powder 
(C) CCT with PEO WSR 301.
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more prevalent during the early hours of the morning 
and because there is no chronotherapeutic formulation 
presently available on the market where the immediate 
release dosage form cannot fulfill the needs of drug 
delivery at the required time. Optimized PEO WSR 301 
and PEO WSR 1105 coated tablets produced the desired 
predetermined lag time, and all the physiochemical pa-
rameters were well within limits. Of these formulations, 
PEO WSR 301 obtained the predetermined lag time 
with a lower concentration of polymer, as the viscosity 
and molecular weight of PEO WSR 301(4000000 & 
1650 -5500 mPas (1% sol)) is higher than that of  PEO 
WSR 1105 (900000 & 8800 – 17600 mPas (5% sol)). 
Hence, these can be exploited to achieve ChrDDs of 
Torsemide for the treatment of hypertension at the time 
the patient needs it. 
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